Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):108-119.

Zhang S, Chiang GC, Knapp JM, Zecca CM, He D, Ramakrishna R, et al. Grading meningiomas utilizing multiparametric MRI with inclusion of susceptibility weighted imaging and quantitative susceptibility mapping. J Neuroradiol. 2020;47(4):272-277.

Nuovo GJ, Magro C, Mikhail A. Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx. Ann Diagn Pathol. 2020;48:151565.

Tosi U, Kommidi H, Adeuyan O, Guo H, Maachani UB, Chen N, et al. PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models. Sci Adv. 2020;6(30):eabb4105.

Vega F, Amador C, Chadburn A, Feldman AL, Hsi ED, Wang W, et al. American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. Ann Diagn Pathol. 2020;49:151623.

Holst JM, Plesner TL, Pedersen MB, Frederiksen H, Møller MB, Clausen MR, et al. Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. Haematologica. 2020;105(10):2432-2439.

Humphries RM, Magnano P, Burnham CA, Bard JD, Dingle TC, Callan K, et al. Evaluation of Surrogate Tests for the Presence of -Mediated Methicillin Resistance in Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus warneri. J Clin Microbiol. 2020;59(1).

Haas T, Cushing MM. Hemostatic Balance in Severe Trauma. Front Pediatr. 2020;8:600501.

Amara SN, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, et al. Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020;11(1):5799.

Lui GY, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.